QUANTRO Therapeutics logo representing the Vienna-based biotechnology company awarded an Austrian FFG research grant for its ASCEND drug discovery platform.
Vienna-based QUANTRO Therapeutics has secured a 12-month research grant from Austria's FFG to develop ASCEND, an AI-driven platform for discovering and optimizing drugs targeting transcription factors. The grant amount was not disclosed.

QUANTRO Therapeutics GmbH, a Vienna, Austria-based biotechnology company developing treatments targeting transcription factors, has received a 12-month, non-dilutive research grant from the Austrian Research Promotion Agency (FFG).

Announced on November 3, 2026, the grant will support the development of ASCEND, QUANTRO’s AI-driven medicinal chemistry platform designed to accelerate drug discovery and the optimization of therapeutic compounds. The financial value of the grant was not disclosed.

The ASCEND platform will integrate QUANTRO’s proprietary time-resolved transcriptomic data with molecular modelling and artificial intelligence and machine learning tools. The system is being developed to support the identification and optimization of small molecules that modulate or degrade transcription factors, including covalent compounds and molecular glues.

According to the company, ASCEND will initially focus on oncology applications, with the potential to expand into other therapeutic areas. The platform will operate primarily on local computing infrastructure in Vienna.

Founded in 2019 as a spin-out from Vienna’s Institute of Molecular Biotechnology (IMBA) and Research Institute of Molecular Pathology (IMP), QUANTRO was scientifically co-founded by Stefan Ameres and Johannes Zuber. The company is led by CEO Michael Bauer.

QUANTRO develops drug discovery technologies focused on transcription factors and gene expression regulators associated with cancer and other diseases, including inflammatory conditions. Its transcriptomic platform measures changes in gene expression over time to identify compounds that affect specific biological targets.

The company has received investment support from Boehringer Ingelheim Venture Fund and Evotec. In August 2024, QUANTRO also received an FFG grant supporting an 18-month research and development project valued at €1.7 million, focused on expanding the screening capabilities of its drug discovery platform.

The latest grant will support the integration of computational drug design and medicinal chemistry capabilities into ASCEND as QUANTRO advances its therapeutic discovery programmes.

Get the latest startup funding news in your inbox.

We don’t spam! Read our privacy policy for more info.

Share